Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-05

AUTHORS

N A Farid, C D Payne, D S Small, K J Winters, C S Ernest, J T Brandt, C Darstein, J A Jakubowski, D E Salazar

ABSTRACT

Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R-138727) is formed primarily by cytochrome P450 (CYP) 3A and CYP2B6, with roles for CYP2C9 and CYP2C19. Clopidogrel's activation involves two sequential steps by CYP3A, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6. In a randomized crossover study, healthy subjects received a loading dose (LD) of prasugrel (60 mg) or clopidogrel (300 mg), followed by five daily maintenance doses (MDs) (15 and 75 mg, respectively) with or without the potent CYP3A inhibitor ketoconazole (400 mg/day). Subjects had a 2-week washout between periods. Ketoconazole decreased R-138727 and clopidogrel active metabolite Cmax (maximum plasma concentration) 34-61% after prasugrel and clopidogrel dosing. Ketoconazole did not affect R-138727 exposure or prasugrel's inhibition of platelet aggregation (IPA). Ketoconazole decreased clopidogrel's active metabolite AUC0-24 (area under the concentration-time curve to 24 h postdose) 22% (LD) to 29% (MD) and reduced IPA 28% (LD) to 33% (MD). We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA. More... »

PAGES

735-741

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139

DOI

http://dx.doi.org/10.1038/sj.clpt.6100139

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1006304268

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17361128


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Pharmacology and Pharmaceutical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clopidogrel", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 CYP3A Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ketoconazole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Piperazines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Platelet Aggregation Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prasugrel Hydrochloride", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiophenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ticlopidine", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Farid", 
        "givenName": "N A", 
        "id": "sg:person.01255414044.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255414044.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Lilly Research Center Ltd Windlesham UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Payne", 
        "givenName": "C D", 
        "id": "sg:person.01224546355.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224546355.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Small", 
        "givenName": "D S", 
        "id": "sg:person.01126325126.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126325126.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Winters", 
        "givenName": "K J", 
        "id": "sg:person.01046045655.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046045655.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ernest", 
        "givenName": "C S", 
        "id": "sg:person.01252000221.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252000221.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brandt", 
        "givenName": "J T", 
        "id": "sg:person.01340774755.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340774755.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Darstein", 
        "givenName": "C", 
        "id": "sg:person.01137756171.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137756171.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Eli Lilly (United States)", 
          "id": "https://www.grid.ac/institutes/grid.417540.3", 
          "name": [
            "Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jakubowski", 
        "givenName": "J A", 
        "id": "sg:person.0756623644.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756623644.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Daiichi Sankyo (United States)", 
          "id": "https://www.grid.ac/institutes/grid.428496.5", 
          "name": [
            "Daiichi Sankyo Inc. Parsippany New Jersey USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salazar", 
        "givenName": "D E", 
        "id": "sg:person.014714657504.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014714657504.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1161/01.cir.0000047060.60595.cc", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010854770"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2002-10-3027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014797573"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.060664", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016886879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1503/cmaj.060664", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016886879"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2141.1985.tb07467.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030449319"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/eurheartj/ehi877", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033526755"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.31.7.815", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034066953"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2006-04-013052", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034582023"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000112378.09325.f9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037144438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.105.007989", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038051799"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.31.1.53", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040947861"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1038/sj.bjp.0703237", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041733321"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa010746", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042739677"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.amjcard.2006.09.078", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050252358"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1161/01.cir.0000099507.32936.c0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051697653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1742-7843.2005.pto960203.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052432532"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/rcm.2813", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052975930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ahj.2006.10.010", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053653581"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0195-668x(03)00442-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1054625464"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0037-1614133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074741659"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1055/s-0037-1613462", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1075277395"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-05", 
    "datePublishedReg": "2007-05-01", 
    "description": "Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R-138727) is formed primarily by cytochrome P450 (CYP) 3A and CYP2B6, with roles for CYP2C9 and CYP2C19. Clopidogrel's activation involves two sequential steps by CYP3A, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6. In a randomized crossover study, healthy subjects received a loading dose (LD) of prasugrel (60 mg) or clopidogrel (300 mg), followed by five daily maintenance doses (MDs) (15 and 75 mg, respectively) with or without the potent CYP3A inhibitor ketoconazole (400 mg/day). Subjects had a 2-week washout between periods. Ketoconazole decreased R-138727 and clopidogrel active metabolite Cmax (maximum plasma concentration) 34-61% after prasugrel and clopidogrel dosing. Ketoconazole did not affect R-138727 exposure or prasugrel's inhibition of platelet aggregation (IPA). Ketoconazole decreased clopidogrel's active metabolite AUC0-24 (area under the concentration-time curve to 24 h postdose) 22% (LD) to 29% (MD) and reduced IPA 28% (LD) to 33% (MD). We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1038/sj.clpt.6100139", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1017409", 
        "issn": [
          "0009-9236", 
          "1532-6535"
        ], 
        "name": "Clinical Pharmacology & Therapeutics", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "5", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "81"
      }
    ], 
    "name": "Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently", 
    "pagination": "735-741", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "1e078ce93f9c4d8e2c19caf286e610f45deca7bc76978a12918b6e7371d5e00a"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17361128"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "0372741"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.clpt.6100139"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1006304268"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.clpt.6100139", 
      "https://app.dimensions.ai/details/publication/pub.1006304268"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:00", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000365_0000000365/records_71704_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100139/abstract"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.clpt.6100139'


 

This table displays all metadata directly associated to this object as RDF triples.

266 TRIPLES      21 PREDICATES      68 URIs      40 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.clpt.6100139 schema:about N05d8d15321464da3a30d712cbca1e599
2 N1b9ed1761d0f467db4b901f4ea7b810b
3 N24935bf1b9a5422eaf0fd62191360f56
4 N2609cdbb6ea54835b1183db652bcd47d
5 N2f8f18a110014c78ac0259b841ef3225
6 N56ab39d6dcf54b1db7b5eca427864e10
7 N7775b514846943a7a586b09b18ee3af3
8 N79c4eed1c15a4677b6ca4d0547d375ff
9 N8dacf6a5c202473d99dc632667dbb019
10 N936acb3b796a4d179326c78079393002
11 N962a3ca03a9f4c64a88099e41c8f8162
12 N9b63c4ab0f2143d693e948a5370e77a9
13 N9d18d6d7d94f4943b2df64e941b3e4c9
14 Na159eb3ed1b048dd903599c59edcd3bb
15 Nabc899e8820c499a937ca25013e4ac44
16 Nb1817e8f3eb94527b7c6f1a3398304cd
17 Nc7d192288e664e3da161dd0860015ea1
18 Nd1a5e16609664b1db2e1a33750cb7b99
19 Nef35a0eb18274350a0308fc86e7f820f
20 anzsrc-for:11
21 anzsrc-for:1115
22 schema:author N4ee7ad7df1d444b2885cc83c6beaa08f
23 schema:citation https://doi.org/10.1002/rcm.2813
24 https://doi.org/10.1016/j.ahj.2006.10.010
25 https://doi.org/10.1016/j.amjcard.2006.09.078
26 https://doi.org/10.1016/s0195-668x(03)00442-1
27 https://doi.org/10.1038/sj.bjp.0703237
28 https://doi.org/10.1055/s-0037-1613462
29 https://doi.org/10.1055/s-0037-1614133
30 https://doi.org/10.1056/nejmoa010746
31 https://doi.org/10.1093/eurheartj/ehi877
32 https://doi.org/10.1111/j.1365-2141.1985.tb07467.x
33 https://doi.org/10.1111/j.1742-7843.2005.pto960203.x
34 https://doi.org/10.1124/dmd.105.007989
35 https://doi.org/10.1124/dmd.31.1.53
36 https://doi.org/10.1124/dmd.31.7.815
37 https://doi.org/10.1161/01.cir.0000047060.60595.cc
38 https://doi.org/10.1161/01.cir.0000099507.32936.c0
39 https://doi.org/10.1161/01.cir.0000112378.09325.f9
40 https://doi.org/10.1182/blood-2002-10-3027
41 https://doi.org/10.1182/blood-2006-04-013052
42 https://doi.org/10.1503/cmaj.060664
43 schema:datePublished 2007-05
44 schema:datePublishedReg 2007-05-01
45 schema:description Prasugrel and clopidogrel inhibit platelet aggregation through active metabolite formation. Prasugrel's active metabolite (R-138727) is formed primarily by cytochrome P450 (CYP) 3A and CYP2B6, with roles for CYP2C9 and CYP2C19. Clopidogrel's activation involves two sequential steps by CYP3A, CYP1A2, CYP2C9, CYP2C19, and/or CYP2B6. In a randomized crossover study, healthy subjects received a loading dose (LD) of prasugrel (60 mg) or clopidogrel (300 mg), followed by five daily maintenance doses (MDs) (15 and 75 mg, respectively) with or without the potent CYP3A inhibitor ketoconazole (400 mg/day). Subjects had a 2-week washout between periods. Ketoconazole decreased R-138727 and clopidogrel active metabolite Cmax (maximum plasma concentration) 34-61% after prasugrel and clopidogrel dosing. Ketoconazole did not affect R-138727 exposure or prasugrel's inhibition of platelet aggregation (IPA). Ketoconazole decreased clopidogrel's active metabolite AUC0-24 (area under the concentration-time curve to 24 h postdose) 22% (LD) to 29% (MD) and reduced IPA 28% (LD) to 33% (MD). We conclude that CYP3A4 and CYP3A5 inhibition by ketoconazole affects formation of clopidogrel's but not prasugrel's active metabolite. The decreased formation of clopidogrel's active metabolite is associated with reduced IPA.
46 schema:genre research_article
47 schema:inLanguage en
48 schema:isAccessibleForFree false
49 schema:isPartOf N025873c2625d40578117978fd0ad8ce7
50 N53991130ed48463fa98f0ec62ad971cd
51 sg:journal.1017409
52 schema:name Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently
53 schema:pagination 735-741
54 schema:productId N0fd6a5d685814aa8928b7dbbfb54d962
55 N3620cc5002cf4277b18da2710f05e890
56 N6328b68e18e248eda2d5600897a9794a
57 Ndfb316d6bf78491da18025886cf0386f
58 Ne51e46ed6a4a41f9959e081ea9c4c7a4
59 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006304268
60 https://doi.org/10.1038/sj.clpt.6100139
61 schema:sdDatePublished 2019-04-11T13:00
62 schema:sdLicense https://scigraph.springernature.com/explorer/license/
63 schema:sdPublisher Nde7a18d5c85740ed97d62845318cd7c3
64 schema:url http://onlinelibrary.wiley.com/doi/10.1038/sj.clpt.6100139/abstract
65 sgo:license sg:explorer/license/
66 sgo:sdDataset articles
67 rdf:type schema:ScholarlyArticle
68 N025873c2625d40578117978fd0ad8ce7 schema:issueNumber 5
69 rdf:type schema:PublicationIssue
70 N05d8d15321464da3a30d712cbca1e599 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Ketoconazole
72 rdf:type schema:DefinedTerm
73 N0a55dfe321e445c19885074dab27c1ea rdf:first sg:person.01252000221.39
74 rdf:rest Nda4fc01be01545ada4810f73cae2cbb1
75 N0fd6a5d685814aa8928b7dbbfb54d962 schema:name doi
76 schema:value 10.1038/sj.clpt.6100139
77 rdf:type schema:PropertyValue
78 N1b9ed1761d0f467db4b901f4ea7b810b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Platelet Aggregation Inhibitors
80 rdf:type schema:DefinedTerm
81 N1c0de254ad7d4d89aea6f9ee8c93ead5 rdf:first sg:person.01137756171.46
82 rdf:rest N3e4a55bf7b7b4394af656a07abd7b39c
83 N24935bf1b9a5422eaf0fd62191360f56 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Humans
85 rdf:type schema:DefinedTerm
86 N2609cdbb6ea54835b1183db652bcd47d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Platelet Aggregation
88 rdf:type schema:DefinedTerm
89 N2f8f18a110014c78ac0259b841ef3225 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Clopidogrel
91 rdf:type schema:DefinedTerm
92 N3620cc5002cf4277b18da2710f05e890 schema:name dimensions_id
93 schema:value pub.1006304268
94 rdf:type schema:PropertyValue
95 N382d223f9fc6411cbda6cf46fe98671b rdf:first sg:person.01046045655.15
96 rdf:rest N0a55dfe321e445c19885074dab27c1ea
97 N3e4a55bf7b7b4394af656a07abd7b39c rdf:first sg:person.0756623644.24
98 rdf:rest N810847c424cc4ef88a2a47f9d9089cbf
99 N4ee7ad7df1d444b2885cc83c6beaa08f rdf:first sg:person.01255414044.69
100 rdf:rest Nd8dc366444bf44ef80d72769c212a533
101 N53991130ed48463fa98f0ec62ad971cd schema:volumeNumber 81
102 rdf:type schema:PublicationVolume
103 N56ab39d6dcf54b1db7b5eca427864e10 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Drug Interactions
105 rdf:type schema:DefinedTerm
106 N6328b68e18e248eda2d5600897a9794a schema:name pubmed_id
107 schema:value 17361128
108 rdf:type schema:PropertyValue
109 N7775b514846943a7a586b09b18ee3af3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Enzyme Inhibitors
111 rdf:type schema:DefinedTerm
112 N79c4eed1c15a4677b6ca4d0547d375ff schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Adult
114 rdf:type schema:DefinedTerm
115 N810847c424cc4ef88a2a47f9d9089cbf rdf:first sg:person.014714657504.26
116 rdf:rest rdf:nil
117 N8dacf6a5c202473d99dc632667dbb019 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Male
119 rdf:type schema:DefinedTerm
120 N936acb3b796a4d179326c78079393002 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Female
122 rdf:type schema:DefinedTerm
123 N9580a24ac5614d6181fb1a18461a6027 rdf:first sg:person.01126325126.28
124 rdf:rest N382d223f9fc6411cbda6cf46fe98671b
125 N962a3ca03a9f4c64a88099e41c8f8162 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Cytochrome P-450 CYP3A Inhibitors
127 rdf:type schema:DefinedTerm
128 N9b63c4ab0f2143d693e948a5370e77a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Piperazines
130 rdf:type schema:DefinedTerm
131 N9d18d6d7d94f4943b2df64e941b3e4c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Thiophenes
133 rdf:type schema:DefinedTerm
134 Na159eb3ed1b048dd903599c59edcd3bb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Ticlopidine
136 rdf:type schema:DefinedTerm
137 Na56afe4d5aa94bed8255e99fd64ba8ea schema:name Lilly Research Center Ltd Windlesham UK
138 rdf:type schema:Organization
139 Nabc899e8820c499a937ca25013e4ac44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Area Under Curve
141 rdf:type schema:DefinedTerm
142 Nb1817e8f3eb94527b7c6f1a3398304cd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Prasugrel Hydrochloride
144 rdf:type schema:DefinedTerm
145 Nc7d192288e664e3da161dd0860015ea1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Double-Blind Method
147 rdf:type schema:DefinedTerm
148 Nd1a5e16609664b1db2e1a33750cb7b99 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Cross-Over Studies
150 rdf:type schema:DefinedTerm
151 Nd8dc366444bf44ef80d72769c212a533 rdf:first sg:person.01224546355.86
152 rdf:rest N9580a24ac5614d6181fb1a18461a6027
153 Nda4fc01be01545ada4810f73cae2cbb1 rdf:first sg:person.01340774755.46
154 rdf:rest N1c0de254ad7d4d89aea6f9ee8c93ead5
155 Nde7a18d5c85740ed97d62845318cd7c3 schema:name Springer Nature - SN SciGraph project
156 rdf:type schema:Organization
157 Ndfb316d6bf78491da18025886cf0386f schema:name nlm_unique_id
158 schema:value 0372741
159 rdf:type schema:PropertyValue
160 Ne51e46ed6a4a41f9959e081ea9c4c7a4 schema:name readcube_id
161 schema:value 1e078ce93f9c4d8e2c19caf286e610f45deca7bc76978a12918b6e7371d5e00a
162 rdf:type schema:PropertyValue
163 Nef35a0eb18274350a0308fc86e7f820f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Middle Aged
165 rdf:type schema:DefinedTerm
166 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
167 schema:name Medical and Health Sciences
168 rdf:type schema:DefinedTerm
169 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
170 schema:name Pharmacology and Pharmaceutical Sciences
171 rdf:type schema:DefinedTerm
172 sg:journal.1017409 schema:issn 0009-9236
173 1532-6535
174 schema:name Clinical Pharmacology & Therapeutics
175 rdf:type schema:Periodical
176 sg:person.01046045655.15 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
177 schema:familyName Winters
178 schema:givenName K J
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01046045655.15
180 rdf:type schema:Person
181 sg:person.01126325126.28 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
182 schema:familyName Small
183 schema:givenName D S
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01126325126.28
185 rdf:type schema:Person
186 sg:person.01137756171.46 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
187 schema:familyName Darstein
188 schema:givenName C
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01137756171.46
190 rdf:type schema:Person
191 sg:person.01224546355.86 schema:affiliation Na56afe4d5aa94bed8255e99fd64ba8ea
192 schema:familyName Payne
193 schema:givenName C D
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01224546355.86
195 rdf:type schema:Person
196 sg:person.01252000221.39 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
197 schema:familyName Ernest
198 schema:givenName C S
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252000221.39
200 rdf:type schema:Person
201 sg:person.01255414044.69 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
202 schema:familyName Farid
203 schema:givenName N A
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255414044.69
205 rdf:type schema:Person
206 sg:person.01340774755.46 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
207 schema:familyName Brandt
208 schema:givenName J T
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01340774755.46
210 rdf:type schema:Person
211 sg:person.014714657504.26 schema:affiliation https://www.grid.ac/institutes/grid.428496.5
212 schema:familyName Salazar
213 schema:givenName D E
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014714657504.26
215 rdf:type schema:Person
216 sg:person.0756623644.24 schema:affiliation https://www.grid.ac/institutes/grid.417540.3
217 schema:familyName Jakubowski
218 schema:givenName J A
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756623644.24
220 rdf:type schema:Person
221 https://doi.org/10.1002/rcm.2813 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052975930
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/j.ahj.2006.10.010 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053653581
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1016/j.amjcard.2006.09.078 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050252358
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1016/s0195-668x(03)00442-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1054625464
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1038/sj.bjp.0703237 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041733321
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1055/s-0037-1613462 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075277395
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1055/s-0037-1614133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074741659
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1056/nejmoa010746 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042739677
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1093/eurheartj/ehi877 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033526755
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1111/j.1365-2141.1985.tb07467.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030449319
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1111/j.1742-7843.2005.pto960203.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1052432532
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1124/dmd.105.007989 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038051799
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1124/dmd.31.1.53 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040947861
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1124/dmd.31.7.815 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034066953
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1161/01.cir.0000047060.60595.cc schema:sameAs https://app.dimensions.ai/details/publication/pub.1010854770
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1161/01.cir.0000099507.32936.c0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051697653
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1161/01.cir.0000112378.09325.f9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037144438
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1182/blood-2002-10-3027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014797573
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1182/blood-2006-04-013052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034582023
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1503/cmaj.060664 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016886879
260 rdf:type schema:CreativeWork
261 https://www.grid.ac/institutes/grid.417540.3 schema:alternateName Eli Lilly (United States)
262 schema:name Lilly Research Laboratories, Eli Lilly and Company Indianapolis Indiana USA
263 rdf:type schema:Organization
264 https://www.grid.ac/institutes/grid.428496.5 schema:alternateName Daiichi Sankyo (United States)
265 schema:name Daiichi Sankyo Inc. Parsippany New Jersey USA
266 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...